# Example: High-Quality Newsletter

This example demonstrates all Every.to techniques properly applied.

---

## The GLP-1 Infrastructure Play You're Missing

Between August 2024 and January 2025, Eli Lilly's market cap climbed from $740 billion to $890 billion—a 20% jump driven almost entirely by tirzepatide demand. Novo Nordisk followed a similar trajectory, crossing $500 billion. The conventional wisdom says these pharma giants own the GLP-1 market.

Here's what that analysis misses: the infrastructure.

The companies capturing the next wave of value aren't the ones making the molecules—they're the ones building the systems that make GLP-1 therapy scalable. Think of it like the early internet: Before Amazon could exist, we needed TCP/IP and HTTP. We're in that moment again, but for metabolic medicine.

## The Compounding Problem

Dr. Sarah Chen at Stanford's metabolic clinic sees it daily: a patient responds beautifully to semaglutide at 0.5mg weekly, but standard titration protocols push them to 2.4mg regardless. The result? Nausea severe enough to cause discontinuation in 23% of cases—a number that drops to 8% with personalized dosing.

The problem isn't the drug. It's the infrastructure between prescription and outcome.

Traditional dosing follows a rigid escalation schedule. What patients actually need—real-time adjustment based on glucose variability, appetite biomarkers, and side effect patterns—requires systems that don't exist in most clinics.

This is where the infrastructure plays emerge.

## Three Companies Building the Rails

The opportunity breaks into three categories: dose optimization, supply chain, and outcome tracking.

**Dose Optimization:** Levels Health—the Austin-based CGM analytics company valued at $150 million—is repositioning from consumer wellness to clinical infrastructure. Their algorithm correlates continuous glucose data with GLP-1 response patterns, enabling dose adjustments based on actual metabolic outcomes rather than standard schedules. Between September 2024 and January 2025, they signed partnerships with three enterprise telehealth platforms.

**Supply Chain:** Hims & Hers made headlines by entering compounded semaglutide, but the infrastructure story is Empower Pharmacy. The Houston-based 503B facility now supplies 40% of the telehealth GLP-1 market. Their advantage isn't manufacturing—it's the EHR integrations that connect prescriber systems directly to fulfillment. Prescription-to-doorstep in 72 hours, compared to 14 days through traditional pharmacy channels.

**Outcome Tracking:** Calibrate Health—backed by $100 million from a]16z and Founders Fund—built the first purpose-built platform for metabolic outcomes. Their system tracks not just weight, but A1c trends, liver enzymes, and cardiovascular risk markers over time. For clinicians, this is the difference between "patient lost 15 pounds" and "patient reduced 10-year cardiovascular risk by 23%."

It's pure infrastructure.

## The Contrarian Case

The obvious objection: won't Eli Lilly and Novo Nordisk build this themselves?

They'll try. Lilly's acquisition of Sigilon in 2023 signaled interest in delivery innovation. But pharmaceutical companies are optimized for molecule development, not software infrastructure. The skills that create blockbuster drugs—clinical trial design, regulatory navigation, manufacturing scale—are different from the skills that build adaptive dosing algorithms and real-time outcome dashboards.

History suggests the infrastructure layer gets built by specialists. AWS wasn't built by retailers. Stripe wasn't built by banks.

## What This Means for Longevity Clinicians

If you're building a metabolic practice, the question isn't whether to prescribe GLP-1 agonists—that's table stakes. The question is which infrastructure stack to build on.

Three decision points:

1. **Dose optimization:** Are you using CGM data to guide titration, or following standard schedules? The clinics seeing 90%+ adherence rates are the former.

2. **Supply chain:** How quickly can your patients access medication? The 14-day pharmacy lag creates a two-week window where motivation decays.

3. **Outcome tracking:** Can you demonstrate long-term metabolic improvement, or just acute weight loss? The former justifies premium pricing; the latter competes with Hims on cost.

The next 18 months will determine which clinicians own this infrastructure layer while others are still waiting for their pharmacy fax to arrive.

---

## Why This Example Works

### Techniques Demonstrated

**Opening:** Concrete scenario with specific numbers ($740B → $890B, 20% jump)

**Colon Technique:** 
- "Here's what that analysis misses: the infrastructure."
- "The problem isn't the drug. It's the infrastructure between prescription and outcome."
- "The opportunity breaks into three categories: dose optimization, supply chain, and outcome tracking."

**Em-Dash Usage:**
- Clarification: "—a 20% jump driven almost entirely by tirzepatide demand"
- Aside: "—the Austin-based CGM analytics company valued at $150 million—"
- Contrast: "—requires systems that don't exist in most clinics"

**One-Sentence Paragraphs:**
- "It's pure infrastructure."
- "History suggests the infrastructure layer gets built by specialists."

**Evidence Cascade:**
- Levels Health example → Empower Pharmacy example → Calibrate Health example
- Connected with "The opportunity breaks into three categories"

**Specificity:**
- "$740 billion to $890 billion" (not "significant growth")
- "23% of cases" (not "many patients")
- "September 2024 and January 2025" (not "recently")
- "40% of the telehealth GLP-1 market" (not "large market share")

**Forward-Looking Close:**
- "The next 18 months will determine which clinicians own this infrastructure layer"
- NOT "In conclusion, we've covered the GLP-1 infrastructure opportunity"

### Rubric Evaluation

1. ✓ Specificity: Names, numbers, timeframes throughout
2. ✓ Evidence cascade: 3 companies stacked with parallel structure
3. ✓ Colon technique: 3+ strategic uses
4. ✓ Em-dash clarity: Used for all three purposes
5. ✓ One-sentence paragraphs: 2 placed at high-impact moments
6. ✓ Concrete opening: Specific market cap numbers and timeframe
7. ✓ Voice authenticity: Confident, specific, no hedging
8. ✓ Forward-looking conclusion: Implications for next 18 months

This passes all 8 criteria.
